CHMP positive for Jesduvroq to treat symptomatic anemia in adults with chronic kidney disease who are on dialysis – GSK

Jesduvroq (daprodustat) from GSK received a positive opinion from the CHMP for the treatment of adult patients for for the treatment of symptomatic anaemia in adults with chronic kidney disease who are on chronic dialysis.

The benefit of Jesduvroq is its ability to correct haemoglobin levels in dialysis-dependent patients, with effects comparable to those seen with erythropoiesis-stimulating agents. The most common side effects are hypertension, thromboembolic events and diarrhoea.

Jesduvroq will be available as film-coated tablets. The active substance of Jesduvroq is daprodustat, an orally administered antianaemic (ATC code: B03XA07). Daprodustat inhibits hypoxia-inducible factor (HIF)-prolyl hydroxylase, thereby stimulating erythropoietin production. This increases iron mobilisation and the production of haemoglobin and red blood cells.